<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549562</url>
  </required_header>
  <id_info>
    <org_study_id>0709-24</org_study_id>
    <secondary_id>R076477-AUT-4002</secondary_id>
    <nct_id>NCT00549562</nct_id>
  </id_info>
  <brief_title>Study of Paliperidone ER in Adolescents and Young Adults With Autism</brief_title>
  <official_title>A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 8-week, prospective open-label study will investigate the effectiveness and
      tolerability of paliperidone ER in adolescents and young adults with autism.
      Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression,
      self-injury, and irritability in adolescents and young adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Irritability subscale of the Aberrant Behavior Checklist (ABC) will be used as the caregiver-rated primary outcome measure. The Clinical Global Impression-Improvement(CGI-I) will be included as a primary outcome measure.</measure>
    <time_frame>At every visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures include the all the other subscales of the ABC, the Vineland Adaptive Behavior Scales,the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Social Responsiveness Scale.</measure>
    <time_frame>To be done at baseline and endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Paliperidone ER</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>8-Week Open-Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone ER</intervention_name>
    <description>Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.</description>
    <arm_group_label>Paliperidone ER</arm_group_label>
    <other_name>Invega</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between ages of 12 and 21 years

          -  Tanner Sage III or IV (post-pubertal)

          -  Diagnostic and Statistical Manual Fourth Edition Text-Revised (DSM-IV-TR) diagnosis
             of autism

          -  Outpatient

          -  Ability to swallow pills

          -  Antipsychotic medication-free for at least 2 weeks

          -  Score of 4 or more on the Clinical Global Impressions Severity Scale

          -  Score of 18 or higher on the Aberrant Behavior Checklist Irritability Scale

          -  Mental age of 18 months or greater based on testing

          -  Subjects must be in good physical health

        Exclusion Criteria:

          -  Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise Specified (PDD
             NOS), Rett's Disorder, childhood disintegrative disorder, schizophrenia, bipolar
             disorder, Fragile X Syndrome, Tuberous Sclerosis

          -  A significant medical condition

          -  An active seizure disorder

          -  Females who are pregnant

          -  Evidence of a prior adequate trial of paliperidone ER

          -  History of neuroleptic malignant syndrome

          -  Hypersensitivity to paliperidone ER
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly A Stigler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Univerity School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Child &amp; Adolescent Psychiatry Clinic- Riley Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 14, 2015</lastchanged_date>
  <firstreceived_date>October 25, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autistic Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
